Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Giant Cell Arteritis: SELECT-GCA
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary) ; Corticosteroid; Prednisolone
- Indications Giant cell arteritis
- Focus Registrational; Therapeutic Use
- Acronyms SELECT-GCA
- Sponsors AbbVie; AbbVie Germany
- 05 Jan 2024 This trial has been Completed in Austria, According to European Clinical Trials Database record.
- 05 Jan 2024 This trial has been Completed in Austria, According to European Clinical Trials Database record.
- 10 Jul 2023 Planned End Date changed from 27 Apr 2025 to 3 Mar 2025.